Your Article Summary
See Latest ArticlesNovel treatments for systemic amyloidosis
International Journal of Clinical Rheumatology, 05/07/09
van Gameren II et al. – Article reviews the current treatments for systemic amyloidoses:
- Current treatment is directed against an ongoing supply of precursor proteins
- Treatment modalities include:
- liver transplantation for transthyretin-related (ATTR) amyloidosis
- elimination of inflammation in amyloid A (AA) amyloidosis and
- intensive chemotherapy in immunoglobulin light chain (AL) amyloidosis
- These therapies often elicit substantial morbidity and mortality or insufficient effectiveness
- Therefore, the search for new, more effective therapies without serious side-effects remains mandatory
- Since cardiac involvement is vital when deciding on therapy, the introduction of N-terminal probrain natriuretic peptide (NT-proBNP) and troponin are of great importance
- New potent precursor-lowering drugs, such as thalidomide, lenalidomide and bortezomib, need to find their place in treatment protocols in AL amyloidosis
Today in Amyloidosis...keeping you current
Receive free subspecialty "5-minute updates" via email
Left Ventricular Ejection Time on Echocardiography Predicts Long-Term Mortality in Light Chain Amyloidosis
Journal of the American Society of Echocardiography, 11/04/09Amyloid arthropathy mimicking seronegative rheumatoid arthritis in multiple myeloma: case reports and review of the literature
Amyloid The Journal of Protein Folding Disorders, 11/18/09Highly purified eicosapentaenoic acid reduces cardio-ankle vascular index in association with decreased serum amyloid A-LDL in metabolic syndrome
Hypertension Research, 11/12/09